These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
125 related articles for article (PubMed ID: 31298997)
1. Circulating tumor cells (CTCs) and cytokeratin 19 (CK19) mRNA as prognostic factors in heavily pretreated patients with metastatic breast cancer. Morales S; Velasco A; Gasol A; Córdoba F; Vidal J; Serrate A; Valls J; Samame JC; Gisbert R; Moral D; Llombart-Cussac A; Salud A; Matias-Guiu X Cancer Treat Res Commun; 2018; 16():13-17. PubMed ID: 31298997 [TBL] [Abstract][Full Text] [Related]
2. Longitudinal enumeration and cluster evaluation of circulating tumor cells improve prognostication for patients with newly diagnosed metastatic breast cancer in a prospective observational trial. Larsson AM; Jansson S; Bendahl PO; Levin Tykjaer Jörgensen C; Loman N; Graffman C; Lundgren L; Aaltonen K; Rydén L Breast Cancer Res; 2018 Jun; 20(1):48. PubMed ID: 29884204 [TBL] [Abstract][Full Text] [Related]
3. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients. Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110 [TBL] [Abstract][Full Text] [Related]
4. The role of circulating tumor cells in metastatic breast cancer: prognostic and predictive value. Bahnassy AA; Saber MM; Mahmoud MG; Abdellateif MS; Abd El-Mooti Samra M; Abd El-Fatah RM; Zekri AN; Salem SE Mol Biol Rep; 2018 Dec; 45(6):2025-2035. PubMed ID: 30229477 [TBL] [Abstract][Full Text] [Related]
5. Prognostic impact of circulating tumor cell apoptosis and clusters in serial blood samples from patients with metastatic breast cancer in a prospective observational cohort. Jansson S; Bendahl PO; Larsson AM; Aaltonen KE; Rydén L BMC Cancer; 2016 Jul; 16():433. PubMed ID: 27390845 [TBL] [Abstract][Full Text] [Related]
6. Real-time HER2 status detected on circulating tumor cells predicts different outcomes of anti-HER2 therapy in histologically HER2-positive metastatic breast cancer patients. Zhang S; Li L; Wang T; Bian L; Hu H; Xu C; Liu B; Liu Y; Cristofanilli M; Jiang Z BMC Cancer; 2016 Jul; 16():526. PubMed ID: 27456503 [TBL] [Abstract][Full Text] [Related]
7. Prospective assessment of the prognostic value of circulating tumor cells and their clusters in patients with advanced-stage breast cancer. Mu Z; Wang C; Ye Z; Austin L; Civan J; Hyslop T; Palazzo JP; Jaslow R; Li B; Myers RE; Jiang J; Xing J; Yang H; Cristofanilli M Breast Cancer Res Treat; 2015 Dec; 154(3):563-71. PubMed ID: 26573830 [TBL] [Abstract][Full Text] [Related]
8. The prognostic value of chemotherapy or endocrine therapy choice according to circulating tumor cell count in HR Shao B; Li H; Zhang J; Liu X; Song G; Jiang H; Yan Y; Wang H; Wang J; Di L Ann Transl Med; 2022 Aug; 10(16):901. PubMed ID: 36111005 [TBL] [Abstract][Full Text] [Related]
9. Gene expression profiles in circulating tumor cells to predict prognosis in metastatic breast cancer patients. Mostert B; Sieuwerts AM; Kraan J; Bolt-de Vries J; van der Spoel P; van Galen A; Peeters DJ; Dirix LY; Seynaeve CM; Jager A; de Jongh FE; Hamberg P; Stouthard JM; Kehrer DF; Look MP; Smid M; Gratama JW; Foekens JA; Martens JW; Sleijfer S Ann Oncol; 2015 Mar; 26(3):510-6. PubMed ID: 25471333 [TBL] [Abstract][Full Text] [Related]
10. Artificial neural network analysis of circulating tumor cells in metastatic breast cancer patients. Giordano A; Giuliano M; De Laurentiis M; Eleuteri A; Iorio F; Tagliaferri R; Hortobagyi GN; Pusztai L; De Placido S; Hess K; Cristofanilli M; Reuben JM Breast Cancer Res Treat; 2011 Sep; 129(2):451-8. PubMed ID: 21710134 [TBL] [Abstract][Full Text] [Related]
11. Prognostic values of cancer associated macrophage-like cells (CAML) enumeration in metastatic breast cancer. Mu Z; Wang C; Ye Z; Rossi G; Sun C; Li L; Zhu Z; Yang H; Cristofanilli M Breast Cancer Res Treat; 2017 Oct; 165(3):733-741. PubMed ID: 28687903 [TBL] [Abstract][Full Text] [Related]
12. Prospective Evaluation of a Circulating Tumor Cell Sensitivity Profile to Predict Response to Cisplatin Chemotherapy in Metastatic Breast Cancer Patients. de Kruijff IE; Sieuwerts AM; Beije N; Prager-van der Smissen WJC; Angus L; Beaufort CM; Van MN; Oomen-de Hoop E; Jager A; Hamberg P; de Jongh FE; Kraan J; Martens JWM; Sleijfer S Front Oncol; 2021; 11():697572. PubMed ID: 34249756 [TBL] [Abstract][Full Text] [Related]
13. Clinical significance of circulating tumor cells (CTCs) with respect to optimal cut-off value and tumor markers in advanced/metastatic breast cancer. Shiomi-Mouri Y; Kousaka J; Ando T; Tetsuka R; Nakano S; Yoshida M; Fujii K; Akizuki M; Imai T; Fukutomi T; Kobayashi K Breast Cancer; 2016 Jan; 23(1):120-127. PubMed ID: 24906662 [TBL] [Abstract][Full Text] [Related]
14. Circulating tumor cells in metastatic breast cancer: from prognostic stratification to modification of the staging system? Dawood S; Broglio K; Valero V; Reuben J; Handy B; Islam R; Jackson S; Hortobagyi GN; Fritsche H; Cristofanilli M Cancer; 2008 Nov; 113(9):2422-30. PubMed ID: 18785255 [TBL] [Abstract][Full Text] [Related]
15. Longitudinally collected CTCs and CTC-clusters and clinical outcomes of metastatic breast cancer. Wang C; Mu Z; Chervoneva I; Austin L; Ye Z; Rossi G; Palazzo JP; Sun C; Abu-Khalaf M; Myers RE; Zhu Z; Ba Y; Li B; Hou L; Cristofanilli M; Yang H Breast Cancer Res Treat; 2017 Jan; 161(1):83-94. PubMed ID: 27771841 [TBL] [Abstract][Full Text] [Related]
16. Circulating tumor cells (CTCs) detected by triple-marker EpCAM, CK19, and hMAM RT-PCR and their relation to clinical outcome in metastatic breast cancer patients. Zhao S; Yang H; Zhang M; Zhang D; Liu Y; Liu Y; Song Y; Zhang X; Li H; Ma W; Zhang Q Cell Biochem Biophys; 2013 Mar; 65(2):263-73. PubMed ID: 22990361 [TBL] [Abstract][Full Text] [Related]
17. Circulating tumor cells as a prognostic marker for efficacy in the randomized phase III JO21095 trial in Japanese patients with HER2-negative metastatic breast cancer. Iwata H; Masuda N; Yamamoto D; Sagara Y; Sato N; Yamamoto Y; Saito M; Fujita T; Oura S; Watanabe J; Tsukabe M; Horiguchi K; Hattori S; Matsuura Y; Kuroi K Breast Cancer Res Treat; 2017 Apr; 162(3):501-510. PubMed ID: 28181129 [TBL] [Abstract][Full Text] [Related]
18. The prognostic impact of circulating tumor cells in subtypes of metastatic breast cancer. Wallwiener M; Hartkopf AD; Baccelli I; Riethdorf S; Schott S; Pantel K; Marmé F; Sohn C; Trumpp A; Rack B; Aktas B; Solomayer EF; Müller V; Janni W; Schneeweiss A; Fehm TN Breast Cancer Res Treat; 2013 Jan; 137(2):503-10. PubMed ID: 23271327 [TBL] [Abstract][Full Text] [Related]
19. Detection of circulating tumor cells using manually performed immunocytochemistry (MICC) does not correlate with outcome in patients with early breast cancer - Results of the German SUCCESS-A- trial. Jueckstock J; Rack B; Friedl TW; Scholz C; Steidl J; Trapp E; Tesch H; Forstbauer H; Lorenz R; Rezai M; Häberle L; Alunni-Fabbroni M; Schneeweiss A; Beckmann MW; Lichtenegger W; Fasching PA; Pantel K; Janni W; BMC Cancer; 2016 Jul; 16():401. PubMed ID: 27387743 [TBL] [Abstract][Full Text] [Related]
20. Significance of Circulating Tumor Cells in Metastatic Triple-Negative Breast Cancer Patients within a Randomized, Phase II Trial: TBCRC 019. Paoletti C; Li Y; Muñiz MC; Kidwell KM; Aung K; Thomas DG; Brown ME; Abramson VG; Irvin WJ; Lin NU; Liu MC; Nanda R; Nangia JR; Storniolo AM; Traina TA; Vaklavas C; Van Poznak CH; Wolff AC; Forero-Torres A; Hayes DF; Clin Cancer Res; 2015 Jun; 21(12):2771-9. PubMed ID: 25779948 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]